Artrya (AYA) investor relations material

Opening remarks and agenda

• Meeting held in person in West Perth with a live Zoom broadcast; voting was in person or by proxy, and polls covered all resolutions.

• Formal business was followed by the CEO presentation and stakeholder questions; eight items were listed, with resolution 8 later withdrawn.

Financial performance review

• Cash of $67.2m and nil debt as at 30 September 2026; FY26 R&D rebate of $4.8m due.

• First U.S. revenue came from Salix Coronary Anatomy subscriptions and per-scan Salix Coronary Plaque fees; five U.S. commercial customers were secured in the last 12 months.

• Plaque scan volumes trended upward across the quarters ended December 2025, March 2026, June 2026 and September 2026.

• The U.S. CCTA market was cited at $4.4bn annually; 2027 CMS reimbursement rates were announced at $395 for CCTA, $950 for plaque assessment and $850 for flow assessment.

• HonorHealth's agreement includes a Salix platform subscription priced at ~$0.5m, plus per-scan fees for plaque and, after clearance, flow.

Board and executive committee updates

• Jeff Le Benger and Helen Kurincic joined the board during the year and stood for re-election, with board support for their appointments.

• Clayton Hatch commenced as CFO in September, bringing U.S. healthcare commercialization experience; a new Chief People Officer and U.S. operations General Manager were also added.

• Audit & Risk and Remuneration & Nominations committees were established to strengthen oversight and address financial and risk matters, board composition, succession and remuneration.

• Recruitment continued for experienced U.S. healthcare personnel and a CTO to lead product and R&D teams.